ReviewFrontiers in nutrition2026
Fisetin as a nutritional senotherapeutic: mechanisms, translational promise, and lessons from chronic kidney disease.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fisetin is a dietary flavonol that has attracted growing interest as a potential modulator of aging biology. In addition to its antioxidant and anti-inflammatory properties, experimental studies suggest that fisetin may influence cellular senescence through senomorphic and, in some contexts, senolytic actions. This has made it an attractive candidate within the wider field of food derived functional ingredients that target age related disease. Chronic kidney disease provides a useful case study for this emerging area because it is characterized by accelerated biological aging, chronic inflammation and fibrosis, and is associated with a high burden of frailty and multimorbidity. In this mini review, we summarize the nutritional and pharmacological features of fisetin, examine its proposed mechanisms of action, and discuss preclinical and early clinical evidence with a particular focus on kidney disease. We argue that fisetin is a promising but still unproven nutritional senotherapeutic. Its translation is limited by uncertainty around dietary exposure vs. pharmacological dosing, incomplete mechanistic understanding
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.